

Amendments to the Specification:

Please replace paragraph beginning on line 26 of page 6 with the following amended paragraph:

Figure 13A. Influence of the amount of CPL₄ incorporated into SPLP on the uptake of SPLP-CPL₄ into BHK cells. Uptake of SPLP containing 0 (●), 2 (■), 3 (⌊), or 4 (◆) mol% CPL₄ was investigated; the uptake of DOPE:DODAC lipoplexes (⌋) is given for comparison. The insertion of CPL₄ into SPLP and the preparation of lipoplexes was performed as described in Materials and Methods, Example II. The SPLP-CPL₄ media contained 40 mM CaCl₂ to prevent aggregation, addition to the BHK cells resulted in dilution of the CaCl₂ concentration to 8 mM. The uptake protocol involved incubation of SPLP-CPL₄ (20 μM total lipid) with 10⁵ BHK cells in DMEM containing 10% FBS. Following incubation, the cells were lysed and uptake of rhodamine-PE was measured as described in Materials and Methods, Example II. **Figure 13B.** Fluorescence micrographs of BHK cells following uptake of SPLP (Panel I) and SPLP containing 4 mol% CPL₄ (Panel II) following a 4 h incubation. The micrographs on the left were taken in the phase contrast mode and those on the right in the (rhodamine) fluorescence mode.

Please replace paragraph beginning on line 4 of page 8 with the following amended paragraph:

Figure 18A. The transfection potency of SPLP-CPL₄ (●) containing 4 mol% CPL₄ and Lipofectin lipoplexes (◆) following extended transfection times with BHK cells. SPLP-CPL₄ and lipoplexes were generated as indicated for Figure 10. BHK cells were transfected in DMEM containing 10% FBS for 24 and 48 h with SPLP-CPL₄ and Lipofectin lipoplexes (charge ratio of 1.5:1) containing 5.0 μg/mL pCMVLuc. Following transfection the luciferase expression levels and cell protein levels were determined in the cell lysate. The luciferase activity was normalized for protein content in the lysate and plotted as a function of

transfection time. **Figure 18B.** The toxicity of SPLP-CPL₄ (●) containing 4 mol% CPL₄ and Lipofectin lipoplexes (◆) as a function of transfection time, as assayed by cell survival based on the protein concentration in the cell lysate.

Please replace paragraph beginning on line 29 of page 8 with the following amended paragraph:

Figure 21. A synthetic scheme for the preparation of cationic-PEG-lipid conjugates having varying amount of charged head groups (**Figure 21Aa.**) Et₃N/CHCl₃; (**Figure 21Bb.**) TFA /CHCl₃; c. Et₃N / CHCl₃ N α , N ϵ -di-t-Boc-L-Lysine N-hydroxysuccinide ester.